1020 First Avenue
King of Prussia
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
331 articles about CSL Behring
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
Vifor Fresenius Medical Care Renal Pharma is pleased to announce that Tavneos® has been included in the revised EULAR AAV management recommendations, as one of several important updates in the 2022 version.
Global biotechnology leader CSL celebrated the official opening of the company's new state-of-the-art research and development center in Waltham, Massachusetts.
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Global biotechnology leader CSL (ASX: CSL) today announced the publication in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8) results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb).
Global biotechnology leader CSL has again been recognized among America's Best Employers by Forbes and Statista.
Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX®, the First and Only Gene Therapy for Hemophilia B
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, was selected by CSL Behring https://www.gilead.com/ as a limited distribution partner for HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy option for hemophilia B.
uniQure N.V. announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogene dezaparvovec from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
The Board of Directors of CSL Limited announces that it has appointed Dr Paul McKenzie as Chief Executive Officer and Managing Director of CSL from 6 March 2023.
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
Global biotechnology leader CSL announced the presentation of data affirming the long-term durability and safety of single-infusion HEMGENIX® in the treatment of certain adults living with hemophilia B at the 64th American Society of Hematology Annual Meeting.
CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates
Global biotech leader CSL (ASX:CSL) today announced results from the preclinical studies of the company's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates, the next generation of mRNA vaccines.
The Institute for Clinical and Economic Review (ICER) concluded that even at a hefty lifetime cost of $2.5 million, gene therapies for hemophilia A and B are worth it.
More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development
Keynote speakers AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK headline one of the industry's largest events for driving collaboration and innovation.
After three years of construction, global biotechnology leader CSL, inaugurated its new EUR 150 million research and development site on the grounds of the research campus in Marburg's Görzhausen Industrial Park.
Global biotech leader CSL announced that all business units will be united as one family under the CSL global brand.
CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology
CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, began a new era in plasma donations, collecting its first plasma donations using leading-edge plasma collection technology that is expected to significantly reduce average collection time – by approximately one-third – and improve the donor experience.
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
At the start of Takeda’s fiscal year on April 1, Ramona Sequeira and Julie Kim stepped into new positions on the company’s executive leadership team and became role models for women.
If approved, etranacogene dezaparvovec would be the first gene therapy treatment for hemophilia B.
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review.
CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Disorders
As part of its ongoing promise to support those living with rare and serious diseases, including bleeding disorders, CSL Behring is donating 500 million international units of coagulation factor therapy to the World Federation of Hemophilia as part of its continued support of the WFH Humanitarian Aid Program.